Paper42908720PubMed
PLXNB2 promotes breast cancer progression and lung metastasis through the AMPK signaling pathway.
Li X and 9 others. Am J Cancer Res, 2026.
Cite this record
ConductScience Library. PLXNB2 promotes breast cancer progression and lung metastasis through the AMPK signaling pathway. Papers, record 42908720. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42908720
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- PLXNB2 promotes breast cancer progression and lung metastasis through the AMPK signaling pathway.
- Journal
- Am J Cancer Res
- Year
- 2026
- Publication types
- Journal Article
- Revised in PubMed
- 2026-10-24
Source PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References23
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 33514835 | Plexin-B2 facilitates glioblastoma infiltration by modulating cell biomechanics. | Commun Biol | 2021 | https://conductscience.org/library/papers/33514835 | PubMed |
| 2 | 39747004 | Invasion of glioma cells through confined space requires membrane tension regulation and mechano-electrical coupling via Plexin-B2. | Nat Commun | 2025 | https://conductscience.org/library/papers/39747004 | PubMed |
| 3 | 37632633 | Expression analysis, clinical significance and potential function of PLXNB2 in acute myeloid leukaemia. | Mol Biol Rep | 2023 | https://conductscience.org/library/papers/37632633 | PubMed |
| 4 | 34754128 | Treatment landscape of triple-negative breast cancer - expanded options, evolving needs. | Nat Rev Clin Oncol | 2022 | https://conductscience.org/library/papers/34754128 | PubMed |
| 5 | 36722641 | Mutated axon guidance gene PLXNB2 sustains growth and invasiveness of stem cells isolated from cancers of unknown primary. | EMBO Mol Med | 2023 | https://conductscience.org/library/papers/36722641 | PubMed |
| 6 | 33734139 | Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. | Chin Med J (Engl) | 2021 | https://conductscience.org/library/papers/33734139 | PubMed |
| 7 | 21966369 | Plexin-B2 negatively regulates macrophage motility, Rac, and Cdc42 activation. | PLoS One | 2011 | https://conductscience.org/library/papers/21966369 | PubMed |
| 8 | 35195687 | AMP-activated protein kinase promotes breast cancer stemness and drug resistance. | Dis Model Mech | 2022 | https://conductscience.org/library/papers/35195687 | PubMed |
| 9 | 39828795 | Gene function revealed at the moment of stochastic gene silencing | Commun Biol | 2025 | https://conductscience.org/library/papers/39828795 | PubMed |
| 10 | 23644529 | AMPK: a contextual oncogene or tumor suppressor? | Cancer Res | 2013 | https://conductscience.org/library/papers/23644529 | PubMed |
| 11 | 38458752 | Biallelic variants in Plexin B2 (PLXNB2) cause amelogenesis imperfecta, hearing loss and intellectual disability. | J Med Genet | 2024 | https://conductscience.org/library/papers/38458752 | PubMed |
| 12 | 33538338 | Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. | CA Cancer J Clin | 2021 | https://conductscience.org/library/papers/33538338 | PubMed |
| 13 | 32193335 | Transcriptional suppression of AMPKα1 promotes breast cancer metastasis upon oncogene activation. | Proc Natl Acad Sci U S A | 2020 | https://conductscience.org/library/papers/32193335 | PubMed |
| 14 | 25762646 | Plexin-B2 promotes invasive growth of malignant glioma. | Oncotarget | 2015 | https://conductscience.org/library/papers/25762646 | PubMed |
| 15 | 39048831 | In vivo interaction screening reveals liver-derived constraints to metastasis. | Nature | 2024 | https://conductscience.org/library/papers/39048831 | PubMed |
| 16 | 32321715 | AMPK Activation by Metformin Promotes Survival of Dormant ER+ Breast Cancer Cells. | Clin Cancer Res | 2020 | https://conductscience.org/library/papers/32321715 | PubMed |
| 17 | 36423520 | HDLBP-stabilized lncFAL inhibits ferroptosis vulnerability by diminishing Trim69-dependent FSP1 degradation in hepatocellular carcinoma. | Redox Biol | 2022 | https://conductscience.org/library/papers/36423520 | PubMed |
| 18 | 35665782 | Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. | N Engl J Med | 2022 | https://conductscience.org/library/papers/35665782 | PubMed |
| 19 | 29100074 | Plexin-B2 Mediates Physiologic and Pathologic Functions of Angiogenin. | Cell | 2017 | https://conductscience.org/library/papers/29100074 | PubMed |
| 20 | 31942000 | Chemosensitization of prostate cancer stem cells in mice by angiogenin and plexin-B2 inhibitors. | Commun Biol | 2020 | https://conductscience.org/library/papers/31942000 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42908720
GET https://conductscience.org/api/papers/v1/42908720/references?page=2